Biochemotherapy, which uses recombinant interferon alpha (rIFN-alpha) and recombinant interleukin-2 (rIL-2) in combination with chemotherapy is a promising therapy for metastatic malignant melanoma. Various biochemotherapy regimens have produced overall objective response rates of > 50% and durable complete remission (CR) in approximately 10%-of treated patients. One such biochemotherapy regimen, consisting of sequential administration of cisplatin, vinblastine, and dacarbazine (CVD regimen) followed by rIFN-alpha and rIL-2, has produced a response rate of 60% and a CR rate of 20% in the most recent cohort of 62 patients treated at The University of Texas M.D. Anderson Cancer Center. The duration of partial responses with this and similar regimens typically averages 6 to 9 months; however, more than half of the CRs achieved with this regimen have been durable for 3+ to 5+ years. This has raised the possibility of long-term survival in approximately 10% of patients with metastatic melanoma. If confirmed, this will represent a significant advance in the treatment of metastatic melanoma.